VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia
VistaGen will receive tiered royalties on sales of PH94B in the Territory, if Phase 3 development efforts are successful.
- VistaGen will receive tiered royalties on sales of PH94B in the Territory, if Phase 3 development efforts are successful.
- VistaGen retains exclusive rights to develop and commercialize PH94B in all markets outside the Territory.
- Our strategic collaboration today with EverInsight positions PH94B one step closer to becoming a potentially paradigm-shifting new treatment alternative for individuals worldwide."
- "We partner with innovative companies that develop novel medicines with large commercial potential in Greater China and other Asian markets.